Testing effectiveness (Phase 2)Ended earlyNCT05162066
What this trial is testing
Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)
Who this might be right for
Complement 3 GlomerulopathyImmunoglobulin A NephropathyMembranous Nephropathy
BioCryst Pharmaceuticals 2